Company Overview of Novartis Pharmaceuticals Corporation
Novartis Pharmaceuticals Corporation researches, develops, manufactures, and markets medicines and treatments for patients in the United States. It offers prescription drugs to treat various diseases and conditions, including cancer, cardiovascular, central nervous system, endocrine, inflammatory, ophthalmic, infectious, neurological, organ transplantation, psychiatric, respiratory, and skin diseases and conditions. The company also provides patient assistance programs. Novartis Pharmaceuticals Corporation was formerly known as Sandoz Pharmaceuticals Corporation and changed its name to Novartis Pharmaceuticals Corporation in March 1997. The company was incorporated in 1968 and is based in Ea...
One Health Plaza
East Hanover, NJ 07936-1080
Founded in 1968
Key Executives for Novartis Pharmaceuticals Corporation
Chief Financial & Administrative Officer and Vice President
Vice President of Communications and US Country Head of Communications
Compensation as of Fiscal Year 2014.
Novartis Pharmaceuticals Corporation Key Developments
Novartis Pharmaceuticals to Lay Off about 200 People from its Primary Care Force
Dec 10 14
Novartis Pharmaceuticals will lay off about 200 people from its primary care force as it shifts emphasis to cardiovascular disease. A notice of the impending layoffs, listed effective February 16, in East Hanover, appeared on state Department of Labor and Workforce Development's website late last week.
Sandoz Unveils Generic Version of Cystic Fibrosis Medication in US
Jul 21 14
Sandoz announced the US market introduction of tobramycin inhalation solution, USP, an authorized generic version of TOBI, currently marketed by Novartis Pharmaceuticals Corporation. Tobramycin inhalation solution, USP is indicated for the management of cystic fibrosis patients whose lungs contain bacteria called P. aeruginosa.
Novartis Pharmaceuticals Announces Executive Appointments
Jul 17 14
Novartis AG announced that Vas Narasimhan is appointed Global Head of Development, Novartis Pharmaceuticals, effective August 1, 2014. Narasimhan joined Novartis in 2005 and will succeed Tim Wright, who has decided to pursue opportunities outside the company and to spend more time with his family. Narasimhan has worked within the Pharmaceuticals and Vaccines businesses and has held the role of Global Head, Development, Novartis Vaccines. In addition, Eric Cornut is appointed Chief Ethics, Compliance and Policy Officer, effective August 1, 2014. Cornut will lead the Integrity & Compliance and Public Affairs functions at Novartis. He has held numerous leadership positions at Novartis, exposing him to many different stakeholder groups. His role as the Chief Commercial Officer at Novartis Pharmaceuticals, as well as previous positions at regional and country levels, have positioned him well to work in partnership with external stakeholders.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|